{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:37:44Z","timestamp":1783953464528,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Aromatic antiepileptic drugs (AEDs)-induced cutaneous adverse drug reactions (cADRs) add up to the limited use of the AEDs in the treatment and prevention of seizures. <jats:italic>Human leukocyte antigen-B<\/jats:italic> (<jats:italic>HLA-B<\/jats:italic>) alleles have been linked to AEDs-induced cADRs. We investigated the association between cADRs (including Stevens\u2013Johnson syndrome; SJS\/toxic epidermal necrolysis; TEN, drug reaction with eosinophilia and systemic symptoms; DRESS, and Maculopapular eruption; MPE) caused by AEDs (phenytoin, carbamazepine, lamotrigine, phenobarbital and oxcarbazepine) and <jats:italic>HLA-B<\/jats:italic> alleles in Thai population. Through the case-control study, 166 patients with AEDs-induced cADRs, 426 AEDs-tolerant patients (AEDs-tolerant controls), and 470 healthy subjects (Thai population) were collected. The <jats:italic>HLA<\/jats:italic> genotypes were detected using the polymerase chain reaction-sequence specific oligonucleotide probe (PCR-SSOP) method. We also performed a meta-analysis with these data and other populations. The carrier rate of <jats:italic>HLA-B*15:02<\/jats:italic> was significantly different between AEDs-induced cADRs group and AEDs-tolerant group (Odds ratio; OR 4.28, 95% Confidence interval; CI 2.64\u20136.95, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), AEDs-induced cADRs group and Thai population (OR 2.15, 95%CI 1.41\u20133.29, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In meta-analysis showed the strong association <jats:italic>HLA-B*15:02<\/jats:italic> with AEDs-induced cADRs (OR 4.77, 95%CI 1.79\u201312.73, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Furthermore, <jats:italic>HLA-B*15:02<\/jats:italic> was associated with SJS\/TEN induced by AEDs (OR 10.28, 95%CI 6.50\u201316.28, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) Phenytoin (OR 4.12, 95%CI 1.77\u20139.59, <jats:italic>p<\/jats:italic>\u2009=\u20090.001) and carbamazepine (OR 137.69, 95%CI 50.97\u2013371.98, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). This study demonstrated that genetic association for AEDs-induced cADRs was phenotype-specific. A strong association between <jats:italic>HLA-B*15:02<\/jats:italic> and AEDs-induced SJS\/TEN was demonstrated with an OR of 10.79 (95%CI 5.50\u201321.16, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) when compared with AEDs-tolerant group. On the other hand, the carrier rates of <jats:italic>HLA-B*08:01<\/jats:italic>, <jats:italic>HLA-B*13:01<\/jats:italic>, and <jats:italic>HLA-B*56:02<\/jats:italic> were significantly higher in the DRESS group compared with the AEDs-tolerant group (<jats:italic>p<\/jats:italic>\u2009=\u20090.029, 0.007, and 0.017, respectively). The <jats:italic>HLA-B*15:02<\/jats:italic> allele may represent a risk factor for AEDs-induced cADRs.<\/jats:p>","DOI":"10.1038\/s41397-021-00247-3","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T17:02:37Z","timestamp":1624726957000},"page":"682-690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Spectrum of cutaneous adverse reactions to aromatic antiepileptic drugs and human leukocyte antigen genotypes in Thai patients and meta-analysis"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0033-5321","authenticated-orcid":false,"given":"Chonlaphat","family":"Sukasem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthida","family":"Sririttha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonlawat","family":"Chaichan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thapanat","family":"Nakkrut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patompong","family":"Satapornpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanoot","family":"Jaruthamsophon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thawinee","family":"Jantararoungtong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napatrupron","family":"Koomdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadeep","family":"Medhasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarawut","family":"Oo-Puthinan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ticha","family":"Rerkpattanapipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jettanong","family":"Klaewsongkram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawinee","family":"Rerknimitr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papapit","family":"Tuchinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Chularojanamontri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napatra","family":"Tovanabutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1424-9347","authenticated-orcid":false,"given":"Naravut","family":"Suvannang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyada","family":"Rungrotmongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surasak","family":"Saokaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichai","family":"Aekplakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apichaya","family":"Puangpetch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"key":"247_CR1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","volume":"11","author":"P Perucca","year":"2012","unstructured":"Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792\u2013802.","journal-title":"Lancet Neurol"},{"key":"247_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14740330903427969","volume":"9","author":"WH Chung","year":"2010","unstructured":"Chung WH, Hung SI, Chen YT. Genetic predisposition of life-threatening antiepileptic-induced skin reactions. Expert Opin Drug Saf. 2010;9:15\u201321.","journal-title":"Expert Opin Drug Saf"},{"key":"247_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","volume":"209","author":"J-C Roujeau","year":"2005","unstructured":"Roujeau J-C. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209:123\u20139.","journal-title":"Toxicology"},{"key":"247_CR4","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1056\/NEJMcp1104080","volume":"366","author":"RS Stern","year":"2012","unstructured":"Stern RS. Exanthematous drug eruptions. N Engl J Med. 2012;366:2492\u2013501.","journal-title":"N Engl J Med"},{"key":"247_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000335627","volume":"97","author":"T Harr","year":"2012","unstructured":"Harr T, French LE. Stevens\u2013Johnson syndrome and toxic epidermal necrolysis. Chem Immunol Allergy. 2012;97:149\u201366.","journal-title":"Chem Immunol Allergy"},{"key":"247_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1590\/S0365-05962012000300013","volume":"87","author":"PR Criado","year":"2012","unstructured":"Criado PR, Criado RF, Avancini JM, Santi CG. Drug reaction with eosinophilia and systemic symptoms (DRESS)\/drug-induced hypersensitivity syndrome (DIHS): a review of current concepts. Bras Dermatol. 2012;87:435\u201349.","journal-title":"Bras Dermatol"},{"key":"247_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jtos.2015.10.002","volume":"14","author":"S Kohanim","year":"2016","unstructured":"Kohanim S, Palioura S, Saeed HN, Akpek EK, Amescua G, Basu S, et al. Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis\u2014a comprehensive review and guide to therapy. I. Systemic disease. Ocul Surf. 2016;14:2\u201319.","journal-title":"Ocul Surf"},{"key":"247_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"WH Chung","year":"2004","unstructured":"Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens\u2013Johnson syndrome. Nature. 2004;428:486.","journal-title":"Nature"},{"key":"247_CR9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","volume":"149","author":"W Tangamornsuksan","year":"2013","unstructured":"Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013;149:1025\u201332.","journal-title":"JAMA Dermatol"},{"key":"247_CR10","first-page":"478","volume":"5","author":"A Puangpetch","year":"2014","unstructured":"Puangpetch A, Koomdee N, Chamnanphol M, Jantararoungtong T, Santon S, Prommas S, et al. HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity. Front Genet. 2014;5:478.","journal-title":"Front Genet"},{"key":"247_CR11","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0198-8859(01)00298-1","volume":"62","author":"K Cao","year":"2001","unstructured":"Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Vina MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol. 2001;62:1009\u201330.","journal-title":"Hum Immunol"},{"key":"247_CR12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"SH Kardaun","year":"2013","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071\u201380.","journal-title":"Br J Dermatol"},{"key":"247_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2217\/pgs.09.162","volume":"11","author":"SI Hung","year":"2010","unstructured":"Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010;11:349\u201356.","journal-title":"Pharmacogenomics"},{"key":"247_CR14","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","volume":"49","author":"C Locharernkul","year":"2008","unstructured":"Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49:2087\u201391.","journal-title":"Epilepsia"},{"key":"247_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5415\/apallergy.2015.5.2.68","volume":"5","author":"DV Nguyen","year":"2015","unstructured":"Nguyen DV, Chu HC, Nguyen DV, Phan MH, Craig T, Baumgart K, et al. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy. 2015;5:68\u201377.","journal-title":"Asia Pac Allergy"},{"key":"247_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/tpj.2016.10","volume":"17","author":"CC Chang","year":"2017","unstructured":"Chang CC, Ng CC, Too CL, Choon SE, Lee CK, Chung WH, et al. Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. Pharmacogenom J. 2017;17:170\u20133.","journal-title":"Pharmacogenom J"},{"key":"247_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.4103\/0378-6323.57718","volume":"75","author":"TY Mehta","year":"2009","unstructured":"Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens\u2013Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009;75:579\u201382.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"247_CR18","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","volume":"9","author":"PB Ferrell","year":"2008","unstructured":"Ferrell PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9:1543\u20136.","journal-title":"Pharmacogenomics"},{"key":"247_CR19","unstructured":"Dean L Phenytoin Therapy and HLA-B*15:02 and CYP2C9 Genotypes. 2016;"},{"key":"247_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1212\/WNL.0000000000003453","volume":"88","author":"CB Chen","year":"2017","unstructured":"Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Jorns TP, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology. 2017;88:78\u201386.","journal-title":"Neurology"},{"key":"247_CR21","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/cpt.1004","volume":"103","author":"EJ Phillips","year":"2018","unstructured":"Phillips EJ, Sukasem C, Whirl-Carrillo M, M\u00fcller DJ, Dunnenberger HM, Chantratita W, et al. Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clin Pharm Ther. 2018;103:574\u201358.","journal-title":"Clin Pharm Ther"},{"key":"247_CR22","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.2217\/pgs.13.180","volume":"14","author":"N Kaniwa","year":"2013","unstructured":"Kaniwa N, Sugiyama E, Saito Y, Kurose K, Maekawa K, Hasegawa R, et al. Specific HLA types are associated with antiepileptic drug-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics. 2013;14:1821\u201331.","journal-title":"Pharmacogenomics"},{"key":"247_CR23","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/epi.13509","volume":"57","author":"W Manuyakorn","year":"2016","unstructured":"Manuyakorn W, Mahasirimongkol S, Likkasittipan P, Kamchaisatian W, Wattanapokayakit S, Inunchot W, et al. Association of HLA genotypes with phenobarbital hypersensitivity in children. Epilepsia 2016;57:1610\u20136.","journal-title":"Epilepsia"},{"key":"247_CR24","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.eplepsyres.2013.05.004","volume":"106","author":"LJ Li","year":"2013","unstructured":"Li LJ, Hu FY, Wu XT, An DM, Yan B, Zhou D. Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese. Epilepsy Res. 2013;106:296\u2013300.","journal-title":"Epilepsy Res"},{"key":"247_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s11596-014-1247-7","volume":"34","author":"D Sun","year":"2014","unstructured":"Sun D, Yu CH, Liu ZS, He XL, Hu JS, Wu GF, et al. Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens\u2013Johnson syndrome in central China. J Huazhong Univ Sci Technol Med Sci. 2014;34:146\u201350.","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"247_CR26","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00228-011-1009-4","volume":"67","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Wang J, Zhao LM, Peng W, Shen GQ, Xue L, et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharm. 2011;67:885\u20137.","journal-title":"Eur J Clin Pharm"},{"key":"247_CR27","first-page":"2780272","volume":"10","author":"C Sukasem","year":"2018","unstructured":"Sukasem C, Chaichan C, Nakkrut T, Satapornpong P, Jaruthamsophon K, Jantararoungtong T, et al. Association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients. J Immunol Res. 2018;10:2780272.","journal-title":"J Immunol Res"},{"key":"247_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","volume":"16","author":"SI Hung","year":"2006","unstructured":"Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genom. 2006;16:297\u2013306. 27","journal-title":"Pharmacogenet Genom"},{"key":"247_CR29","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","volume":"48","author":"CB Man","year":"2007","unstructured":"Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48:1015\u20138. 28","journal-title":"Epilepsia"},{"key":"247_CR30","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","volume":"51","author":"N Kaniwa","year":"2010","unstructured":"Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010;51:2461\u20135.","journal-title":"Epilepsia"},{"key":"247_CR31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","volume":"97","author":"SH Kim","year":"2011","unstructured":"Kim SH, Lee KW, Song WJ, Kim SH, Jee YK, Lee SM, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011;97:190\u20137.","journal-title":"Epilepsy Res"},{"key":"247_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep45553","volume":"7","author":"K Jaruthamsophon","year":"2017","unstructured":"Jaruthamsophon K, Tipmanee V, Sangiemchoey A, Sukasem C, Limprasert P. HLA-B*15:21 and carbamazepine-induced Stevens\u2013Johnson syndrome: pooled-data and in silico analysis. Sci Rep. 2017;7:45553.","journal-title":"Sci Rep"},{"key":"247_CR33","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2217\/pgs-2017-0103","volume":"18","author":"R Yuliwulandari","year":"2017","unstructured":"Yuliwulandari R, Kristin E, Prayuni K, Sachrowardi Q, Suyatna FD, Menaldi SL, et al. Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype. Pharmacogenomics 2017;18:1643\u20138.","journal-title":"Pharmacogenomics"},{"key":"247_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41397-019-0143-8","volume":"20","author":"F Capule","year":"2020","unstructured":"Capule F, Tragulpiankit P, Mahasirimongkol S, Jittikoon J, Wichukchinda N, Theresa Alentajan-Aleta L, et al. Association of carbamazepine-induced Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients. Pharmacogenom J. 2020;20:533\u201341.","journal-title":"Pharmacogenom J"},{"key":"247_CR35","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00228-017-2250-2","volume":"73","author":"K Yampayon","year":"2017","unstructured":"Yampayon K, Sukasem C, Limwongse C, Chinvarun Y, Tempark T, Rerkpattanapipat T, et al. Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. Eur J Clin Pharm. 2017;73:855\u201365.","journal-title":"Eur J Clin Pharm"},{"key":"247_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/FPC.0000000000000211","volume":"26","author":"W Tassaneeyakul","year":"2016","unstructured":"Tassaneeyakul W, Prabmeechai N, Sukasem C, Kongpan T, Konyoung P, Chumworathayi P, et al. Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genom. 2016;26:225\u201334.","journal-title":"Pharmacogenet Genom"},{"key":"247_CR37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/pds.4979","volume":"29","author":"C Sukasem","year":"2020","unstructured":"Sukasem C, Sririttha S, Tempark T, Klaewsongkram J, Rerkpattanapipat T, Puangpetch A, et al. Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population. Pharmacoepidemiol Drug Saf. 2020;29:565\u201374.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"247_CR38","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cpt.1190","volume":"105","author":"SC Su","year":"2019","unstructured":"Su SC, Chen CB, Chang WC, Wang CW, Fan WL, Lu LY, et al. HLA alleles and CYP2C9*3 as predictors of phenytoin hypersensitivity in East Asians. Clin Pharm Ther. 2019;105:476\u201385.","journal-title":"Clin Pharm Ther"},{"key":"247_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fphar.2020.00078","volume":"11","author":"P Satapornpong","year":"2020","unstructured":"Satapornpong P, Jinda P, Jantararoungtong T, Koomdee N, Chaichan C, Pratoomwun J, et al. Genetic diversity of HLA class I and class II alleles in thai populations: contribution to genotype-guided therapeutics. Front Pharm. 2020;11:78.","journal-title":"Front Pharm"},{"key":"247_CR40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1034\/j.1399-0039.2000.550402.x","volume":"55","author":"M Takiguchi","year":"2000","unstructured":"Takiguchi M, Matsuda T, Tomiyama H, Miwa K. Analysis of three HLA-A*3303 binding peptide anchors using an HLA-A*3303 stabilization assay. Tissue Antigens 2000;55:296\u2013302.","journal-title":"Tissue Antigens"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-021-00247-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-021-00247-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-021-00247-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:00:45Z","timestamp":1684616445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-021-00247-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["247"],"URL":"https:\/\/doi.org\/10.1038\/s41397-021-00247-3","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]},"assertion":[{"value":"29 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving human participants were reviewed and approved by the ethics committee of Ramathibodi Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}